HC Wainwright reissued their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a report issued on Thursday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.
Other analysts also recently issued reports about the stock. Cantor Fitzgerald reiterated an overweight rating on shares of Spero Therapeutics in a report on Tuesday, August 6th. TD Cowen raised Spero Therapeutics from a hold rating to a buy rating in a report on Tuesday, August 6th.
Get Our Latest Research Report on SPRO
Spero Therapeutics Trading Up 0.8 %
Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Spero Therapeutics had a net margin of 14.74% and a return on equity of 25.67%. The business had revenue of $10.20 million during the quarter, compared to analyst estimates of $9.80 million. During the same period last year, the firm posted ($0.23) EPS. On average, research analysts predict that Spero Therapeutics will post -1.59 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC bought a new position in Spero Therapeutics during the first quarter valued at $31,000. Renaissance Technologies LLC raised its position in shares of Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after buying an additional 121,492 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after acquiring an additional 418,742 shares during the last quarter. Murchinson Ltd. grew its position in Spero Therapeutics by 1.3% in the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after acquiring an additional 11,210 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in Spero Therapeutics during the fourth quarter worth approximately $1,570,000. 25.60% of the stock is owned by hedge funds and other institutional investors.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Featured Stories
- Five stocks we like better than Spero Therapeutics
- What is MarketRank™? How to Use it
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Ride Out The Recession With These Dividend Kings
- MarketBeat Week in Review – 9/30 – 10/4
- ESG Stocks, What Investors Should Know
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.